Table 2. PET/SPECT GABAA/BDZ receptor availability data sets: clinical characteristics of the samples.
| First author | Year | Patient group |
Sample size |
SCZ %M | SCZ age mean | %AP | %BZ | PANSS | DOI | |
|---|---|---|---|---|---|---|---|---|---|---|
| C | SCZ | |||||||||
| Busatto67 | 1997 | SCZ | 12 | 15 | 93 | 29 | 60 | NR | NR | 6.5 |
| Verhoeff70 | 1999 | SCZ | 24 | 25 | 100 | 41 | 80 | 0 | NR | NR |
| Abi-Dargham71 | 1999 | SCZ | 16 | 16 | 100 | 44 | 69 | 0 | NR | NR |
| Asai72 | 2008 | SCZ | 11 | 12 | 55 | 33 | 0 | 0 | 90.4 | NR |
| Lee74 | 2013 | SCZ | 18 | 17 | 47 | 29 | 100 | 0 | 60.5 | 4.1 |
| Kang73 | 2014 | CHR | 15 | 11 | 66 | 19 | 18 | 0 | NR | — |
| Frankle75 | 2015 | SCZ | 22 | 17 | 65 | 28 | 0 | NR | 83 | NR |
Abbreviations: %AP, percentage of SCZ group currently taking antipsychotic medication; %BZ, percentage of SCZ group currently taking benzodiazepine or anticonvulsant medication; C, control; CHR, clinical high risk; DOI, mean duration of illness in years; %M, percentage of male in SCZ sample; NR, not reported; PANSS, Positive and Negative Syndrome Scale mean total symptom score; SCZ, schizophrenia. Age is expressed in years, mean; regional effect sizes are provided in Figure 2.